Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2020

View Archived Issues

New targets, new booster for CAR-T cells

As nanoparticles, vitamins fight sepsis

Targeting SMPD1 ameliorates leptin resistance-derived endothelial dysfunction in rats

ViiV Healtcare's Dovato receives approval in Japan for HIV infection

Cynata receives approval for its U.K. phase II study in critical limb ischemia

Kannalife presents additional data regarding the MOA of its leading candidate KLS-13019

NantKwest announces phase I data for PD-L1t.haNK

Alexion plans to initiate pivotal phase III CHAMPION-ALS study of Ultomiris in ALS

TROP2-targeted photoimmunotherapy shows promise in preclinical models

Zuclomiphene reduces moderate to severe hot flashes in men with prostate cancer on ADT

TCP-25 wound gel targets wound infection and inflammation in vivo

Cts Biopharma describes new anti-marinobufagenin antibodies

Cugene patents interleukin-2 variants

Kite Pharma discloses vectors encoding recombinant therapeutic T cells receptors

New gemcitabine prodrugs discovered at Shanghai Changchengyiyaokeji

Conatus Pharmaceuticals discovers caspase inhibitors

New STING receptor agonists discovered at Eternity Bioscience

Subtypes take on new importance as KRAS inhibitors proceed

NOTCH3 genetic variant found as a risk factor of stroke

Investigators report ZUMA-2 results with KTE-X19 in mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...